First Manhattan’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Manhattan’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$957	–	1415
2023 Q4	$957	Buy	+4	New	+$681	﹤0.01%	1333
2020 Q1	–	Sell	-10	Closed	-$1K	–	1361
2019 Q4	$1K	Buy	+10	New	+$997	﹤0.01%	1262
2016 Q4	–	Sell	-2,000	Closed	-$135K	–	1365
2016 Q3	$135K	Hold	2,000	–	–	﹤0.01%	741
2016 Q2	$110K	Hold	2,000	–	–	﹤0.01%	795
2016 Q1	$125K	Hold	2,000	–	–	﹤0.01%	745
2015 Q4	$188K	Hold	2,000	–	–	﹤0.01%	684
2015 Q3	$160K	Hold	2,000	–	–	﹤0.01%	708
2015 Q2	$239K	Hold	2,000	–	–	﹤0.01%	657
2015 Q1	$208K	Hold	2,000	–	–	﹤0.01%	680
2014 Q4	$194K	Hold	2,000	–	–	﹤0.01%	705
2014 Q3	$156K	Hold	2,000	–	–	﹤0.01%	725
2014 Q2	$126K	Hold	2,000	–	–	﹤0.01%	770
2014 Q1	$134K	Buy	2,000 +1,000	+100%	+$77.4K	﹤0.01%	742
2013 Q4	$64K	Buy	+1,000	New	+$59.7K	﹤0.01%	882

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan's ALNY Position: Q1 2024 in Review

First Manhattan sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 4 shares — an estimated $957 sold.

First Manhattan first reported a position in ALNY in Q4 2013 and held it in 14 quarters. The position peaked at $239K in Q2 2015. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

First Manhattan reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
First Manhattan sold 4 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $957.
First Manhattan first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 14 quarters.
First Manhattan's Alnylam Pharmaceuticals position peaked at $239K in Q2 2015.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on First Manhattan's 13F filing for Q1 2024, filed 15 May 2024.